Kupando
Private Company
Funding information not available
Overview
Kupando is a private, preclinical-stage biotech pioneering a novel therapeutic approach using dual TLR4/7 agonists to stimulate innate and trained immunity. Its lead asset, KUP101, is being developed for tissue-agnostic solid tumors and AMR infections, with CTA-enabling studies underway for cutaneous squamous cell carcinoma. The company's platform offers a differentiated, host-directed mechanism with potential as monotherapy or in combination, backed by preclinical proof-of-concept and non-dilutive funding from the German Federal Ministry of Education and Research.
Technology Platform
Proprietary small molecule dual agonists targeting Toll-Like Receptors 4 and 7 (TLR4/7) to stimulate innate immunity and induce trained immunity.
Opportunities
Risk Factors
Competitive Landscape
Kupando competes with other companies developing TLR agonists (e.g., GSK, Idera Pharmaceuticals, Vaxcyte) and innate immune stimulants for oncology and adjuvants. Its differentiation lies in the specific dual TLR4/7 small molecule approach and the focus on inducing trained immunity, but it must demonstrate superior efficacy or safety to succeed in a crowded field.